Literature DB >> 34313128

Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study.

Manuel A Llanos1, Melisa E Gantner1, Santiago Rodriguez1, Lucas N Alberca1, Carolina L Bellera1, Alan Talevi1, Luciana Gavernet1.   

Abstract

The scientific community is working against the clock to arrive at therapeutic interventions to treat patients with COVID-19. Among the strategies for drug discovery, virtual screening approaches have the capacity to search potential hits within millions of chemical structures in days, with the appropriate computing infrastructure. In this article, we first analyzed the published research targeting the inhibition of the main protease (Mpro), one of the most studied targets of SARS-CoV-2, by docking-based methods. An alarming finding was the lack of an adequate validation of the docking protocols (i.e., pose prediction and virtual screening accuracy) before applying them in virtual screening campaigns. The performance of the docking protocols was tested at some level in 57.7% of the 168 investigations analyzed. However, we found only three examples of a complete retrospective analysis of the scoring functions to quantify the virtual screening accuracy of the methods. Moreover, only two publications reported some experimental evaluation of the proposed hits until preparing this manuscript. All of these findings led us to carry out a retrospective performance validation of three different docking protocols, through the analysis of their pose prediction and screening accuracy. Surprisingly, we found that even though all tested docking protocols have a good pose prediction, their screening accuracy is quite limited as they fail to correctly rank a test set of compounds. These results highlight the importance of conducting an adequate validation of the docking protocols before carrying out virtual screening campaigns, and to experimentally confirm the predictions made by the models before drawing bold conclusions. Finally, successful structure-based drug discovery investigations published during the redaction of this manuscript allow us to propose the inclusion of target flexibility and consensus scoring as alternatives to improve the accuracy of the methods.

Entities:  

Year:  2021        PMID: 34313128     DOI: 10.1021/acs.jcim.1c00404

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  12 in total

1.  A virtual drug-screening approach to conquer huge chemical libraries.

Authors:  Charlotte Deane; Maranga Mokaya
Journal:  Nature       Date:  2022-01       Impact factor: 49.962

Review 2.  Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.

Authors:  Kaifu Gao; Rui Wang; Jiahui Chen; Limei Cheng; Jaclyn Frishcosy; Yuta Huzumi; Yuchi Qiu; Tom Schluckbier; Xiaoqi Wei; Guo-Wei Wei
Journal:  Chem Rev       Date:  2022-05-20       Impact factor: 72.087

3.  Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.

Authors:  Davide Deodato; Nadeem Asad; Timothy M Dore
Journal:  Bioorg Med Chem Lett       Date:  2022-06-24       Impact factor: 2.940

Review 4.  A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?

Authors:  Guillem Macip; Pol Garcia-Segura; Júlia Mestres-Truyol; Bryan Saldivar-Espinoza; Gerard Pujadas; Santiago Garcia-Vallvé
Journal:  Int J Mol Sci       Date:  2021-12-27       Impact factor: 5.923

5.  Best practices for repurposing studies.

Authors:  Richard A Lewis
Journal:  J Comput Aided Mol Des       Date:  2021-11-12       Impact factor: 3.686

6.  Predicting Antifouling Activity and Acetylcholinesterase Inhibition of Marine-Derived Compounds Using a Computer-Aided Drug Design Approach.

Authors:  Susana P Gaudêncio; Florbela Pereira
Journal:  Mar Drugs       Date:  2022-02-08       Impact factor: 5.118

7.  Machine learning prediction of 3CLpro SARS-CoV-2 docking scores.

Authors:  Lukas Bucinsky; Dušan Bortňák; Marián Gall; Ján Matúška; Viktor Milata; Michal Pitoňák; Marek Štekláč; Daniel Végh; Dávid Zajaček
Journal:  Comput Biol Chem       Date:  2022-02-26       Impact factor: 3.737

8.  Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies.

Authors:  Sakshi Piplani; Puneet Singh; Nikolai Petrovsky; David A Winkler
Journal:  Front Mol Biosci       Date:  2022-03-14

Review 9.  Finding a chink in the armor: Update, limitations, and challenges toward successful antivirals against flaviviruses.

Authors:  Thamil Vaani Komarasamy; Nur Amelia Azreen Adnan; William James; Vinod Rmt Balasubramaniam
Journal:  PLoS Negl Trop Dis       Date:  2022-04-28

10.  Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study.

Authors:  Mohammed Baqur S Al-Shuhaib; Hayder O Hashim; Jafar M B Al-Shuhaib
Journal:  Comput Biol Med       Date:  2021-12-17       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.